Osteosarcoma
244
57
78
82
Key Insights
Highlights
Success Rate
75% trial completion
Published Results
33 trials with published results (14%)
Research Maturity
82 completed trials (34% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
11.5%
28 terminated out of 244 trials
74.5%
-12.0% vs benchmark
4%
9 trials in Phase 3/4
40%
33 of 82 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 82 completed trials
Clinical Trials (244)
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
Losartan + Sunitinib in Treatment of Osteosarcoma
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Newly Diagnosed, Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
Safety and Feasibility of Intraoperative Visualization With Cytalux in Children
Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
Musculoskeletal Cancers Remote Monitoring and Care
Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma
Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients
the Exploration of MTAP Deletion in Osteosarcoma by Immunohistochemistry
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
An Organoid-based Functional Precision Medicine Trial in Osteosarcoma
Expanded Access Use of L-MTP-PE for the Treatment of Osteosarcoma
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas